ATE373077T1 - Verfahren zur herstellung von cs6- antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli- infektionen - Google Patents

Verfahren zur herstellung von cs6- antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli- infektionen

Info

Publication number
ATE373077T1
ATE373077T1 AT03709279T AT03709279T ATE373077T1 AT E373077 T1 ATE373077 T1 AT E373077T1 AT 03709279 T AT03709279 T AT 03709279T AT 03709279 T AT03709279 T AT 03709279T AT E373077 T1 ATE373077 T1 AT E373077T1
Authority
AT
Austria
Prior art keywords
treating
preventing
methods
escherichia coli
enterotoxigenic escherichia
Prior art date
Application number
AT03709279T
Other languages
English (en)
Inventor
Frederick Cassels
James Wood
Original Assignee
Us Army Medical Res & Materiel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army Medical Res & Materiel filed Critical Us Army Medical Res & Materiel
Application granted granted Critical
Publication of ATE373077T1 publication Critical patent/ATE373077T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03709279T 2002-02-25 2003-02-24 Verfahren zur herstellung von cs6- antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli- infektionen ATE373077T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36110502P 2002-02-25 2002-02-25
US42180402P 2002-10-29 2002-10-29

Publications (1)

Publication Number Publication Date
ATE373077T1 true ATE373077T1 (de) 2007-09-15

Family

ID=27807904

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709279T ATE373077T1 (de) 2002-02-25 2003-02-24 Verfahren zur herstellung von cs6- antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli- infektionen

Country Status (7)

Country Link
US (1) US7217541B2 (de)
EP (1) EP1481053B1 (de)
AT (1) ATE373077T1 (de)
AU (1) AU2003213233B2 (de)
CA (1) CA2477273A1 (de)
DE (1) DE60316258D1 (de)
WO (1) WO2003076643A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372708B1 (de) * 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Impstoffe zur transkutanen immunisierung gegen reisediarrhö
US20040208928A1 (en) * 2003-04-15 2004-10-21 Animal Technology Institute Taiwan Method for preparing an orally administrable formulation for controlled release
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält
CN103917244B (zh) 2011-09-12 2016-07-06 斯堪的纳维亚生物制药控股公司 用于提高细胞表面的etec cs6抗原呈递的方法及可由其获得的产物
EP2897638A1 (de) 2012-09-24 2015-07-29 Montana State University-Bozeman Rekombinanter lactococcus lactis zur expression des escherichia coli-kolonisationsfaktor-antigens i (cfa/i) fimbriae und verfahren zu deren verwendung
WO2017142887A1 (en) 2016-02-15 2017-08-24 Modern Meadow, Inc. Biofabricated material containing collagen fibrils

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
ES2075325T3 (es) * 1990-04-20 1995-10-01 Akzo Nobel Nv Subunidad de vacuna contra el actinobacillus pleuropneumoniae.
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
SE9401921D0 (sv) 1994-06-03 1994-06-03 Sbl Vaccin Ab A method of cultivating bacteria
US5914114A (en) 1995-06-02 1999-06-22 The United States Of America As Represented By The Secretary Of The Army Method of raising antibodies against E. coli of the family CS4-CFA/I
US5698416A (en) * 1995-06-02 1997-12-16 The United States Of America As Represented By The Secretary Of The Army Methods for production of antigens under control of temperature-regulated promotors in enteric bacteria
MXPA02010407A (es) * 2000-04-20 2003-05-23 Univ Maryland Aislamiento y caracterizacion del operante csa (etec-cs4-pili) y metodos para su uso.
EP1372708B1 (de) * 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Impstoffe zur transkutanen immunisierung gegen reisediarrhö

Also Published As

Publication number Publication date
WO2003076643A3 (en) 2004-09-10
EP1481053A4 (de) 2005-06-22
EP1481053B1 (de) 2007-09-12
AU2003213233B2 (en) 2009-02-05
AU2003213233A1 (en) 2003-09-22
US7217541B2 (en) 2007-05-15
WO2003076643A2 (en) 2003-09-18
CA2477273A1 (en) 2003-09-18
EP1481053A2 (de) 2004-12-01
US20040005662A1 (en) 2004-01-08
DE60316258D1 (de) 2007-10-25

Similar Documents

Publication Publication Date Title
DE602004030239D1 (de) Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon
HUP0100723A2 (hu) Indolszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
NO990362L (no) Nye stammer av Echerichia coli, metoder for fremstilling og bruk av disse i fermenteringsprosesser for produksjon av L-treonin
RU94046367A (ru) Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
ATE17082T1 (de) Verfahren zur herstellung von polysaccharidprotein-komplexenaus bakterienhuellen, die hergestellten produkte und dieselben enthaltende immunogenische zusammensetzungen.
ATE180408T1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
GB0313916D0 (en) Vaccine composition
CY1106926T1 (el) Γονιδιο που κωδικοποιει την ηλιομυκινη και η χρηση της
DE60133817D1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
EP1481053A4 (de) Verfahren zur herstellung von cs6-antigenimpfstoff zur behandlung, vorbeugung oder hemmung enterotoxigener escherichia coli-infektionen
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
BRPI0415010A8 (pt) forma cristalina, composto, processo para preparar os mesmos, métodos para tratar uma condição associada com excesso de taquicininas, uso do composto cristalino, e, composição farmacêutica
EA200600778A1 (ru) 1,3-диметилбутилкарбоксанилиды для борьбы с нежелательными микроорганизмами
ATE476982T1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE602004030541D1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
EP0347682A3 (de) Polycarbonate mit mesogenen Verbindungen als Endgruppen, ihre Herstellung und Verwendung
DE602004023100D1 (de) Verbindungen und verfahren zur behandlung von dyslipidemie
DK2335720T3 (da) Autolog T-cellevacciner mod multiple sclerose
DE60330864D1 (de) Neue verbindungen, deren verwendung und herstellung
ATE349531T1 (de) Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung
ATE442361T1 (de) Verfahren zur herstellung kristalliner formen von orlistat
EA200600777A1 (ru) N-замещённые пиразолилкарбоксанилиды
DE69026585D1 (de) Verfahren zur Herstellung von R-(-)-3-Halogeno-1,2-propandiol durch Behandlung mit Mikroorganismen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties